Multivariate analysis for OS in treatment-naïve patients, WHO 2008 blast-based subgroups
| Variable . | P . | HR . | 95% CI for HR . | |
|---|---|---|---|---|
| WHO 2008 (CMML-1 vs CMML-2) | .0182 | 0.757 | 0.601 | 0.954 |
| Hemoglobin concentration | <.0001 | 0.864 | 0.820 | 0.910 |
| FAB subtype (MDS vs MP) | <.0001 | 0.517 | 0.414 | 0.645 |
| CPSS cytogenetic risk | ||||
| High vs low | <.0001 | 2.428 | 1.796 | 3.282 |
| Intermediate vs low | .3465 | 1.170 | 0.844 | 1.623 |
| Age (<70 y vs ≥70 y) | .0078 | 0.740 | 0.593 | 0.924 |
| Variable . | P . | HR . | 95% CI for HR . | |
|---|---|---|---|---|
| WHO 2008 (CMML-1 vs CMML-2) | .0182 | 0.757 | 0.601 | 0.954 |
| Hemoglobin concentration | <.0001 | 0.864 | 0.820 | 0.910 |
| FAB subtype (MDS vs MP) | <.0001 | 0.517 | 0.414 | 0.645 |
| CPSS cytogenetic risk | ||||
| High vs low | <.0001 | 2.428 | 1.796 | 3.282 |
| Intermediate vs low | .3465 | 1.170 | 0.844 | 1.623 |
| Age (<70 y vs ≥70 y) | .0078 | 0.740 | 0.593 | 0.924 |